Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

226
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
226
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

915
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
915
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

154
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
154
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

132
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
132
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

509
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
509
Angina IV: Management01:26

Angina IV: Management

159
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
159

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Patterns of Communicating the Diagnosis of Type 1 vs Type 2 Myocardial Infarction.

JACC. Advances·2026
Same author

Validity of the International Classification of Diseases, Tenth Revision codes in diagnosing myocardial infarction subtypes.

American heart journal·2026
Same author

Analytical Performance Evaluation of the Cardiac Troponin T High Sensitivity Gen 6 Assay.

The journal of applied laboratory medicine·2026
Same author

Passing the Torch?: A Next-Generation High-Sensitivity Cardiac Troponin T Assay.

Journal of the American College of Cardiology·2026
Same author

Guiding Preventive Care Strategies for Patients With Atherosclerotic Plaque on Coronary CTA: Primary Outcomes of the DECIDE Registry.

JACC. Cardiovascular imaging·2026
Same author

Real-World Adoption of the 2021 Kidney Disease: Improving Global Outcomes Blood Pressure Guideline in CKD.

Journal of the American Society of Nephrology : JASN·2026

相关实验视频

Updated: Dec 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K

在慢性冠状动脉综合征的二次预防中为所有人提供终身阿司匹林:仍然是神圣的还是需要重新评估?

Alan P Jacobsen1, Inbar Raber2, Cian P McCarthy3

  • 1Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD(A.P.J., R.S.B., J.W.M.).

Circulation
|September 4, 2020
PubMed
概括

阿司匹林

关键词:
没有阿司匹林心肌缺血症二次预防

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.8K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.6K

相关实验视频

Last Updated: Dec 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.8K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.6K

科学领域:

  • 心脏病学
  • 药理学

背景情况:

  • 阿司匹林几十年来一直是心肌梗塞的第二次预防的基石.
  • 在心肌梗塞后的立即阶段已确立有效性.
  • 新出现的证据质疑其在慢性冠状动脉综合征 (CCS) 中的普遍性和终身作用.

研究的目的:

  • 审查目前关于阿司匹林在二次预防CCS中的作用的证据.
  • 评估最近的试验挑战阿司匹林在终身CCS管理中的优势.
  • 讨论当代心血管风险管理的影响.

主要方法:

  • 最近的临床试验和元分析的叙述性审查.
  • 在特定的CCS患者群体中分析涉及停用阿司匹林的研究数据.
  • 考虑初级预防试验结果及其对二次预防的相关性.

主要成果:

  • 最近的试验显示在特定情况下可能停止阿司匹林治疗 (例如,双重抗血小板治疗,CCS/ AFib中的抗凝固治疗).
  • 具有最佳风险因素管理的初级预防试验并未始终显示阿司匹林的净益处.
  • 随着二次预防策略的发展,阿司匹林在CCS中的相对有效性可能会改变.

结论:

  • 所有CCS患者对阿司匹林的普遍需求需要进一步调查.
  • 对于高出血风险的稳定老年患者,建议特别小心.
  • 当代的二次预防疗法可能需要重新评估阿司匹林的作用.